1. The antitumor activity of olaparib in PDXs identifies a subset of PARPi‐sensitive tumors
The antitumor activity of olaparib in PDXs identifies a subset of PARPi‐sensitive tumors AWaterfall plot showing the percentage of tumor volume change in olaparib‐treated tumors compared to the tumor volume on day % and −30% are marked by dotted lines to indicate the range of PR, SD, and PD. The box underneath summarizes different characteristics of each model and the clinical context at the moment of PDX implantation. Black boxes indicate the presence of the phenotype. TNBC, triple negative breast cancer; ER+BC, estrogen receptor positive breast cancer; P, primary; M, metastasis. Error bars indicate SEM from independent tumors (n ≥ 3).BGraph showing the percentage of tumor volume change during olaparib treatment in PDXs from cohort‐1. Olaparib‐sensitive models are represented with discontinuous lines. Acquisition of PARPi resistance in PDX302, STG201, and PDX093 after prolonged exposure to olaparib is shown.
Marta Castroviejo‐Bermejo et al. EMBO Mol Med. 2018;emmm
© as stated in the article, figure or figure legend